Xintian Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 16.1809 million yuan, a year-on-year decrease of 73.47%Zhitong·Oct 30, 2025 at 03:43 AM002873+2.54%
Xintian Pharma's controlling shareholder, Xintian Zhiyao, plans to reduce its holdings by no more than 7.05 million sharesZhitong·Oct 20, 2025 at 09:02 AM002873+2.54%
Xintian Pharma: Xinlikang capsules approved to conduct clinical trials for the treatment of cancer-related fatigueZhitong·Oct 14, 2025 at 03:37 AM002873+2.54%
Xintian Pharma establishes a new company in traditional Chinese medicine health technologyZhitong·Sep 4, 2025 at 04:11 AM002873+2.54%
Xintian Pharma: Subsidiary Zhongdao Health registered capital of 10 million yuanZhitong·Sep 3, 2025 at 04:48 AM002873+2.54%
Xintian Pharma's subsidiary has obtained an invention patent for the "Ginkgo Biloba Water Decoction Fingerprint Map"Zhitong·Sep 3, 2025 at 03:35 AM002873+2.54%
The A-share traditional Chinese medicine sector rapidly surged, with Xintian Pharma hitting the limit up, and YIBAI PHARMACEUTICAL, Zhendong Pharmacy, ZHONGSHENGYAOYE, Hansen Pharmaceutical, and ENWEI PHARMACEUTICAL following suitZhitong·Aug 24, 2025 at 08:52 PM301331+3.88%002873+2.54%
The three major A-share indices rose collectively, with a significant increase in the biopharmaceutical sector. CPO continues to squeeze shorts, while Hong Kong stocks fluctuated and fell, tech stocks retreated, and government bonds and commodities declinedWallstreetcn·Aug 19, 2025 at 03:25 AM002873+2.54%600557+1.42%
The innovative drug sector surged in the short term, with Chimin hitting the daily limitZhitong·Aug 18, 2025 at 08:32 PM603222+2.29%002873+2.54%
The concept of innovative drugs remains active, with Xintian Pharma and others hitting the daily limitZhitong·Jul 31, 2025 at 08:42 PM002287+0.38%600513+3.34%
Xintian Pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 5.7661 million yuan, a decrease of 80.99%Zhitong·Jul 30, 2025 at 03:39 AM002873+2.54%
Xintian Pharma: Expected net profit in the first half of 2025 to decrease by 83.52% - 76.93% year-on-yearZhitong·Jul 14, 2025 at 05:14 AM002873+2.54%
Xintian Pharma: Received a dividend payment of 15 million yuan from its wholly-owned subsidiaryZhitong·Jun 12, 2025 at 04:26 AM002873+2.54%
Xintian Pharma has been reported for bribing over a hundred doctors, and the Sichuan Health Commission responded that an investigation is underwayWallstreetcn·May 27, 2025 at 05:13 AM002873+2.54%
